Abell Pest Control Marks World Honey Bee Day with New Support for Canadian Bee Gut Research at University of Guelph GlobeNewswire August 14, 2025 Toronto, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) — Ahead of World Honey Bee Day on August 16, Abell Pest Control is strengthening its commitment to pollinator health by supporting the Canadian […]
Milestone Reflects Growing Demand for High-Conviction, Tactical Exposure to the Innovation Economy. Tradr ETFs,a provider of ETFs designed for sophisticated investors and professional traders, proudly announces that it has surpassed $1 billion in assets under management (AUM) just over one year after its launch in May 2024. This significant achievement underscores investor confidence in the
Will focus on high-performance solutions for new construction and rehabilitation projects Bright Power has announced a change in its leadership team. Adin Meir has joined the team as Vice President of New Construction and will lead and manage sustainability services, commissioning, and on-site generation consulting for Bright Power. Carmel Pratt, previously leading the New Construction
Revenue for the Six Months Ended June 30, 2025 Increased 25% Income from Operations for the Six Months Ended June 30, 2025 Increased 202% Net Income for the Six Months Ended June 30, 2025 Increased 168% The Company currently holds 170,687 common shares in Treasury from its Repurchase Program SCOTTSDALE, AZ / ACCESS Newswire /
(NASDAQ:VIVS), SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as
(NasdaqGM:CADL), Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) Received FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 for the treatment of prostate cancer Preparations on
(NASDAQ:OTLK),(NASDAQ:OTLKW), First commercial sales of LYTENAVA(TM) (bevacizumab gamma) achieved in Europe ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for
On September 2nd, 2025, from 8 a.m. to 11 a.m. (EDT) / 9 a.m. to 12 p.m. (Brasília time), we invite you to a digital meeting in which our executives will share the developments in our businesses and their impact on UX. https://mma.prnewswire.com/media/2600067/5120544/ITAU_LOGO_POS_HEX_680X680_Logo.jpg To take part in the event, register at the following link: Itaú
eCap, the leading community and event platform for skilled nursing facility (SNF), operators, healthcare executives and investors, today announced the launch of Catalyst, a high-impact Long-term Care startup showcase and innovation accelerator debuting at eCapWest this fall in Phoenix, AZ. https://mma.prnewswire.com/media/2750351/eCapWest25.jpg Designed in response to the growing need for practical, scalable innovation in healthcare, the
Boost.ai Positioned as a Leader for its Ability to Execute and Completeness of Vision Boost.ai, a leading developer of AI Agents for regulated enterprises, today announced it has been recognized as a Leader by Gartner in the 2025 Magic Quadrant for Conversational AI Platforms. Boost.ai has been recognized in this Magic Quadrant by Gartner for